Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 129 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Edetate Disodium Clear all
Completed Phase 4 Interventional Results available

Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction

NCT02597543
View directory record Official record
Conditions
Heart Transplant, Acute Graft Rejection, Chronic Graft Rejection
Interventions
Regadenoson, Gadolinium, Cardiac MRI
Drug · Procedure
Lead sponsor
Paul Kim
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 27, 2026, 5:15 PM EDT
Not listed Phase 4 Interventional

Tilmanocept vs Sulfur Colloid in Sentinel Lymph Node Biopsy

NCT03199560
View directory record Official record
Conditions
Sentinel Lymph Node Biopsy, Breast Cancer
Interventions
Tc 99m tilmanocept, Tc 99m filtered sulfur colloid
Drug
Lead sponsor
Memorial Health University Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Savannah, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Oct 27, 2026, 5:15 PM EDT
Recruiting Phase 2 Interventional

Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation

NCT05501756
View directory record Official record
Conditions
Allogeneic Hematopoietic Cell Transplantation
Interventions
Alemtuzumab
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 27, 2026, 5:15 PM EDT
Recruiting Phase 1 Interventional

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

NCT03630991
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome, Very High Risk Myelodysplastic Syndrome
Interventions
Edetate Calcium Disodium, Multivitamin, Succimer
Drug · Dietary Supplement
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 27, 2026, 5:15 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions

NCT01211873
View directory record Official record
Conditions
Diagnostic Self Evaluation, Central Nervous System Diseases
Interventions
Dotarem (gadoterate meglumine), Magnevist (gadopentetate dimeglumine)
Drug
Lead sponsor
Guerbet
Industry
Eligibility
2 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • Indian Wells, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 27, 2026, 5:15 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease

NCT02947022
View directory record Official record
Conditions
Headache, Cognitive Disturbance, Skin Hyperpigmentation, Arthralgia
Interventions
Calcium DTPA, Zinc DTPA
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 27, 2026, 5:15 PM EDT
Completed Phase 1Phase 2 Interventional

Monoclonal Antibody Therapy in Treating Patients With Leukemia

NCT00019227
View directory record Official record
Conditions
Lymphoma, Radiation Toxicity
Interventions
pentetic acid calcium, yttrium Y 90 daclizumab
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 27, 2026, 5:15 PM EDT
Terminated Not applicable Interventional

Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases

NCT02967380
View directory record Official record
Conditions
Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Choroid Plexus Neoplasm, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Grade II Meningioma, Adult Medulloblastoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Papillary Meningioma, Adult Pineal Gland Astrocytoma, Adult Pineoblastoma, Adult Primary Melanocytic Lesion of Meninges, Adult Supratentorial Primitive Neuroectodermal Tumor, Malignant Adult Intracranial Hemangiopericytoma, Metastatic Malignant Neoplasm in the Brain, Multiple Sclerosis, Recurrent Adult Brain Neoplasm
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Gadobenate Dimeglumine, Gadobutrol, Gadopentetate Dimeglumine
Procedure · Drug · Radiation
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 27, 2026, 5:15 PM EDT
Terminated Early Phase 1 Interventional

4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy

NCT01034514
View directory record Official record
Conditions
Lung Cancer
Interventions
Real-time Position Management system, Discovery ST multislice PET/CT scanner, Infinia Hawkeye SPECT/CT gamma camera, Pinnacle3 treatment planning system, SKYLight nuclear camera, DTPA, TECHNETIUM TC 99M MAA
Device · Drug
Lead sponsor
Billy W. Loo Jr.
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Oct 27, 2026, 5:15 PM EDT
Completed Phase 1 Interventional Results available

An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)

NCT03157167
View directory record Official record
Conditions
Kaposi Sarcoma, HIV Infections
Interventions
Tc99m-tilmanocept
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 27, 2026, 5:15 PM EDT
Not listed Phase 1Phase 2 Interventional

ASIS for Botox in Cervical Dystonia

NCT02074293
View directory record Official record
Conditions
Cervical Dystonia Adults ,, Abnormal Head Position and Neck Pain for These 7 Muscle Groups: Splenius,Scalene,Sterno-cleido-mastoid,Levator Scapulae,Semispinalis,Trapezius,and Longissimus.
Interventions
Gadolinium, Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, Efficacy of Botox intramuscularly at Week 30, Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, Efficacy of Botox subdermally at Week 30, Adverse Reactions of Botox intramuscularly, Adverse Reactions of Botox subdermally
Drug
Lead sponsor
li nguyen
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Westminster, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Oct 27, 2026, 5:15 PM EDT
Not listed Phase 3 Interventional

NB-001 Treatment of Recurrent Herpes Labialis

NCT01695187
View directory record Official record
Conditions
Herpes Labialis
Interventions
NB-001 (0.3%), Placebo
Drug
Lead sponsor
NanoBio Corporation
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
12
States / cities
Chandler, Arizona • Tucson, Arizona • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2013 · Synced Oct 27, 2026, 5:15 PM EDT
Terminated Phase 3 Interventional Results available

Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma

NCT00911326
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
Lymphoseek
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
13
States / cities
Birminham, Alabama • La Jolla, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2014 · Synced Oct 27, 2026, 5:15 PM EDT
Completed Phase 2 Interventional Results available

Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)

NCT01902953
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
Lymphoseek and VBD Sln dissection
Drug
Lead sponsor
Maimonides Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 27, 2026, 5:15 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Inducing Self-Dehumanization to Examine Oxytocin and Suicide Risk

NCT06710964
View directory record Official record
Conditions
Mechanistic Self-Dehumanization Condition, Control Condition
Interventions
The Ten Item Personality Inventory, Mechanistic Self-Dehumanization Condition, Debrief, Control Condition, Clinical Interview, Self-Report Measures, Blood Draw
Other · Diagnostic Test
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 27, 2026, 5:15 PM EDT
Terminated No phase listed Observational

Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection

NCT05236387
View directory record Official record
Conditions
Breast Cancer
Interventions
99m Tc-TM
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 27, 2026, 5:15 PM EDT
Completed Not applicable Interventional

MRI and CT Scans to Evaluate Invasive Cervical Cancer Before Treating Patients

NCT00004936
View directory record Official record
Conditions
Cervical Cancer
Interventions
iodinated contrast dye, computed tomography, magnetic resonance imaging, gadopentetate dimeglumine
Drug · Procedure · Radiation
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
2
States / cities
Morristown, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Oct 27, 2026, 5:15 PM EDT
Completed Phase 2 Interventional

Magnetic Resonance Imaging in Women Receiving Chemotherapy for Stage III Breast Cancer

NCT00043017
View directory record Official record
Conditions
Breast Cancer
Interventions
MRI/MRS, gadopentetate dimeglumine
Procedure · Radiation
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older · Female only
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2013 · Synced Oct 27, 2026, 5:15 PM EDT
Terminated Phase 1 Interventional

Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium

NCT02589366
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Lymphoseek plus Vital Blue Dye
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 27, 2026, 5:15 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Novel Dental Gel as an Adjunct to Scaling and Root Planing

NCT05384132
View directory record Official record
Conditions
Periodontal Diseases, Gingival Diseases, Gingival Pocket, Gum Bleed, Plaque, Dental
Interventions
SRP + Livfresh Dental Gel, SRP + standard flouride dentifrice
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 85 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 27, 2026, 5:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sublingual vs IV Atropine Bioavailability Study

NCT04290039
View directory record Official record
Conditions
Toxic Effect of Organophosphate and Carbamate Insecticides
Interventions
Atropine Sulfate Ophthalmic Solution, Atropine Sulphate Injection
Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 27, 2026, 5:15 PM EDT
Not listed Phase 1Phase 2 Interventional

ASIS for Botox in Chronic Migraine

NCT02074163
View directory record Official record
Conditions
Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer.
Interventions
Gadolinium, Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24,, Efficacy of Botox intramuscularly at Week 30, Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, Efficacy of Botox subdermally at Week 30, Adverse Reactions of Botox intramuscularly, Adverse Reactions of Botox subdermally
Drug
Lead sponsor
ASIS Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Westminster, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Oct 27, 2026, 5:15 PM EDT
Terminated Phase 1 Interventional

Mapping Draining Lymph Nodes in CNS Malignancies

NCT04096716
View directory record Official record
Conditions
Central Nervous System Neoplasms, Central Nervous System Tumor
Interventions
Tc-99m tilmanocept
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 27, 2026, 5:15 PM EDT
Completed Not applicable Interventional Results available

SPECT/CT in Measuring Lung Function in Patients With Cancer Undergoing Radiation Therapy

NCT01982123
View directory record Official record
Conditions
Lung Carcinoma, Malignant Neoplasm
Interventions
SPECT/CT, Single Photon Emission Computed Tomography, Technetium Tc-99m Albumin Aggregated, Technetium Tc-99m DTPA
Diagnostic Test · Procedure · Radiation + 1 more
Lead sponsor
University of Washington
Other
Eligibility
19 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 27, 2026, 5:15 PM EDT